ArticleACS omega2025
Leveraging Nanotechnology for Safer Herbicide Use: Insights from Maize Tolerance to Nanoencapsulated Atrazine.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous work has shown that nanoencapsulation of atrazine enhances the herbicidal action of this active ingredient. This increased activity is expected to control weeds and not compromise the tolerance of maize plants to the herbicide. This study aimed to evaluate the tolerance of maize plants to atrazine in postemergence application with different nanoformulations. Parameters of photosystem II (PSII) activity and growth of the maize plants in a greenhouse were evaluated after application of the formulations: conventional atrazine (ATZ), atrazine encapsulated in nanocapsules (NCs) of poly-(ε-caprolactone) (PCL + ATZ), PCL coated with chitosan (PCL/CS + ATZ), and zein (ZN + ATZ), at doses of 1000 and 2000 g active ingredient (a.i.) ha
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.